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Arterial Occlusive Disease’Thanks for considering our article.
One of the purpose of our article is to prove the safety after allo-
genic stem cell injection.
As the items to prove the safety, risk of death, cardiac events,
cerebrovascular event, and GVHD could be considered.
We know well as you pointed out, there is no risk of GVHD
related with our procedure. But many of the reviewers insisted to
check the risk of the GVHD.
Also we did not put much emphasis on GVHD in our article. We
also mentioned the death rate, cardiac events, cerebrovascular
event and laboratory ﬁndings.
And you also mentioned about the efﬁcacy with allogenic stem
cell injection.
We agreed with your opinion. Our original article included the
efﬁcacy parts. But the reviewer wanted deletion of efﬁcacy part
due to the small number of clinical experience. So we deleted the
efﬁcacy part.
Once again thanks for your interest in our article.
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Type B Diseases?We would like to congratulate S.G. Thrumurthy et al1 on the
systematic review they did on TEVAR. It seems to me that their
conclusions are almost correct, especially if we take into account
a published multicenter Brazilian experience with TEVAR,2 in 225
patients, of which 174 include aneurysms of the descending aorta.
From this paper there are a few points that should be taken into
account, such as, the similar rates of endoleaks, neurological compli-
cations and reintervention. What the authors seem to lack is a long
term follow-up of this type of treatment and the true results of the
implanted prostheses. Almeida et al2 found that, at leastwith theﬁrst
generationof prostheses, the long termevolution isnot as good as the
initial results, with a necessity for reintervention inmore than 40% of
the cases, at almost 10 years of follow-up. A prospective work on
conventional and endovascular treatment of this type of disease
should be performed to conclude which type of treatment is safer
and most durable, for the patient, as it was stated before.3References
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